IP Library Granted Patent US 12,516,365
Granted Patent B2
US 12,516,365 · App. 17/591,296 · Granted Jan 6, 2026

Biocide compositions compatible with enzyme biosensors and methods of use thereof

Inventors: Dennis Robert Conlon (Shirley, MA); Prasad Pamidi (Burlington, MA)
Assignee: Instrumentation Laboratory Company
C12Q1/18C12Q1/34G01N33/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,365
App. No.
17/591,296
Granted
Jan 6, 2026
Kind
B2
Abstract

The present disclosure relates to biocide compositions compatible with enzyme biosensors and methods for using same. More particularly, the disclosure relates to biocide compositions compatible with enzymes used for measuring creatine and creatinine levels.

Claims (35)

1 . A system comprising:

an in vitro critical care analyzer configured to perform multiple different assays and to measure multiple different analytes, the in vitro critical care analyzer comprising:

a cartridge for the in vitro critical care analyzer, the cartridge being configured for insertion into the in vitro critical care analyzer, the cartridge comprising:

a sensor comprising:

an electrode;

an enzyme layer over the electrode, the enzyme layer comprising one or more enzymes for measurement of one or more of creatine, creatinine, urea, or blood urea nitrogen; and

a diffusion control membrane over the enzyme layer; and

containers holding solutions that are different, that are liquid, and that are to contact the sensor for different purposes, one or more of the solutions comprising one or more biocides, the one or more biocides comprising Levofloxacin or Polymyxin.

2 . The system of claim 1 , wherein the one or more biocides are Levofloxacin.

3 . The system of claim 1 , wherein the sensor comprises a creatinine sensor.

4 . The system of claim 1 , wherein the one or more biocides are Polymyxin.

5 . The system of claim 1 , wherein the Polymyxin is at a concentration of 10 to 100 mg/L (milligrams per liter) in the solution.

6 . The system of claim 1 , wherein the one or more biocides further comprise one or more of the following biocides: Carbenicillin disodium, Spectinomycin, Piperacillin, Ceftazidime, Streptomycin, Sulfanilamide, Sulfathiazole sodium, Sulfadimethoxine, or polyhexamethylene biguanide hydrochloride; and

wherein the polymyxin comprises Polymyxin B or Polymyxin E.

7 . The system of claim 1 , wherein the one or more biocides further comprise one or more of the following biocides: moxycillin, ampicillin, carbenicillin, cefazolin, cefepime, cefoxitin, ceftazidime, clavulanic acid, imipenem, oxacillin, penicillin, or piperacillin.

8 . The system of claim 1 , wherein the one or more of the solutions comprise a process control solution (PCS), a calibration solution, a quality control solution, a conditioning solution, or a wash solution.

9 . The system of claim 1 , wherein the sensor is configured to measure a concentration of one or more analytes in a solution of the one or more solutions.

10 . The system of claim 9 , wherein the one or more biocides are Levofloxacin.

11 . The system of claim 9 , wherein the one or more biocides further comprise one or more of the following biocides: Carbenicillin disodium, Spectinomycin, Piperacillin, Ceftazidime, Streptomycin, Sulfanilamide, Sulfathiazole sodium, Sulfadimethoxine, or polyhexamethylene biguanide hydrochloride; and

wherein the polymyxin comprises Polymyxin B or Polymyxin E.

12 . A system comprising:

a cartridge for an in vitro critical care analyzer, the cartridge being configured for insertion into the in vitro critical care analyzer, the cartridge comprising:

a sensor comprising:

an electrode; and

an enzyme layer over the electrode, the enzyme layer comprising one or more enzymes for measurement of one or more of creatine, creatinine, urea, or blood urea nitrogen; and

containers holding liquid solutions that are different and that are to contact the sensor for different purposes, one or more of the liquid solutions comprising:

an enzyme compatible biocide comprising Levofloxacin or Polymyxin.

13 . The system of claim 1 , wherein the one or more biocides comprise polymyxin E at a concentration of about 10 mg/L (milligrams/liter), about 15 mg/L, about 20 mg/L, about 25 mg/L, about 30 mg/L, about 35 mg/L, about 40 mg/L, about 45 mg/L, or about 50 mg/L.

14 . The system of claim 1 , wherein the one or more solutions comprise at least one of creatine or creatinine.

15 . The system of claim 12 , wherein the enzyme compatible biocide further comprises one or more of the following biocides: Carbenicillin disodium, Spectinomycin, Piperacillin, Ceftazidime, Streptomycin, Sulfanilamide, Sulfathiazole sodium, Sulfadimethoxine, or polyhexamethylene biguanide hydrochloride.

16 . The system of claim 12 , wherein the enzyme compatible biocide further comprises one or more of the following biocides: moxycillin, ampicillin, carbenicillin, cefazolin, cefepime, cefoxitin, ceftazidime, clavulanic acid, imipenem, oxacillin, penicillin, or piperacillin.

17 . The system of claim 12 , wherein the polymyxin comprises Polymyxin B or Polymyxin E.

18 . The system of claim 1 , wherein the containers are selected from a vial, an ampule, a bottle, a carboy, a jar, a sealed Mylar bag, a plastic bag, or a foil laminate bag.

19 . The system of claim 12 , wherein the containers are selected from a vial, an ampule, a bottle, a carboy, a jar, a sealed Mylar bag, a plastic bag, or a foil laminate bag.

20 . The system of claim 12 , wherein the one or more of the liquid solutions comprise a process control solution (PCS), a calibration solution, a quality control solution, a conditioning solution, or a wash solution.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2022
From: CONLON, DENNIS ROBERT; PAMIDI, PRASAD
To: INSTRUMENTATION LABORATORY COMPANY
Reel/Frame 060052/0879 →
Continuity (2)
Continuation 16664264 · Oct 25, 2019
Related Publication 20220154244A1 · May 19, 2022
References Cited (121)
US 2585501A · Leon et al. · 1952 [cited by applicant]
US 2728704A · Edds et al. · 1955 [cited by applicant]
US 3689646A · Sevag et al. · 1972 [cited by applicant]
US 4526783A · Cole et al. · 1985 [cited by applicant]
US 5135924A · Brandt et al. · 1992 [cited by applicant]
US 5202427A · Umezawa et al. · 1993 [cited by applicant]
US 5283005A · Nelson et al. · 1994 [cited by applicant]
US 5464747A · Eisenbeis et al. · 1995 [cited by applicant]
US 5506216A · Schmidt et al. · 1996 [cited by applicant]
US 5585544A · Cheney et al. · 1996 [cited by applicant]
US 5741663A · Russell · 1998 [cited by applicant]
US 6051389A · Ahl et al. · 2000 [cited by applicant]
US 6071392A · Yamamoto · 2000 [cited by applicant]
US 6368847B1 · Line et al. · 2002 [cited by applicant]
US 6767441B1 · Cai · 2004 [cited by applicant]
US 6841527B2 · Mitra et al. · 2005 [cited by applicant]
US 6861232B2 · Schaffar et al. · 2005 [cited by applicant]
US 6960466B2 · Pamidi et al. · 2005 [cited by applicant]
US 7285198B2 · Douglas · 2007 [cited by applicant]
US 7632672B2 · Pamidi et al. · 2009 [cited by applicant]
US 7815788B2 · Schaffar et al. · 2010 [cited by applicant]
US 7960164B2 · Olstein · 2011 [cited by applicant]
US 8268604B2 · Collier et al. · 2012 [cited by applicant]
US 8404096B2 · Purvis et al. · 2013 [cited by applicant]
US 8426192B2 · Pamidi et al. · 2013 [cited by applicant]
US 8466345B2 · Martinell et al. · 2013 [cited by applicant]
US 8501457B2 · Li et al. · 2013 [cited by applicant]
US 9029118B1 · Olstein · 2015 [cited by applicant]
US 9487811B2 · Zhao et al. · 2016 [cited by applicant]
US 11293890B2 · Xu et al. · 2022 [cited by applicant]
US 11327042B2 · Xu et al. · 2022 [cited by applicant]
US 11460431B2 · Xu et al. · 2022 [cited by applicant]
US 11761921B2 · Xu · 2023 [cited by applicant]
US 20040163949A1 · Sorensen · 2004 [cited by applicant]
US 20040211666A1 · Pamidi et al. · 2004 [cited by applicant]
US 20040256227A1 · Shin et al. · 2004 [cited by applicant]
US 20060094120A1 · Clark · 2006 [cited by applicant]
US 20060222564A1 · Dale et al. · 2006 [cited by applicant]
US 20060275857A1 · Kjaer et al. · 2006 [cited by applicant]
US 20060286625A1 · Mcilroy et al. · 2006 [cited by applicant]
US 20070034512A1 · Yamaoka · 2007 [cited by applicant]
US 20070131548A1 · Winarta · 2007 [cited by applicant]
US 20080173064A1 · Schaffar et al. · 2008 [cited by applicant]
US 20080260763A1 · Feigner et al. · 2008 [cited by applicant]
US 20100227345A1 · LeJuene et al. · 2010 [cited by applicant]
US 20130186755A1 · Chu · 2013 [cited by applicant]
US 20140224671A1 · Koide · 2014 [cited by applicant]
US 20160054334A1 · Biessen et al. · 2016 [cited by applicant]
US 20170007616A1 · Gardner · 2017 [cited by applicant]
US 20170107535A1 · Narva et al. · 2017 [cited by applicant]
US 20170254771A1 · Balasubramanian et al. · 2017 [cited by applicant]
US 20170283771A1 · Telfer et al. · 2017 [cited by applicant]
US 20180187151A1 · Guillonneau et al. · 2018 [cited by applicant]
US 20200319210A1 · Xu et al. · 2020 [cited by applicant]
US 20220187234A1 · Xu et al. · 2022 [cited by applicant]
CN 103609425B · 2014 [cited by applicant]
EP 1825255B1 · 2011 [cited by applicant]
EP 1753872B1 · 2014 [cited by applicant]
EP 3397162 · 2017 [cited by examiner]
EP 3397162B1 · 2023 [cited by applicant]
GB 2122900A · 1984 [cited by applicant]
JP H09504179A · 1997 [cited by applicant]
JP 2000507457A · 2000 [cited by applicant]
JP 2003533679A · 2003 [cited by applicant]
JP 2004528579A · 2004 [cited by applicant]
JP 2005501254A · 2005 [cited by applicant]
JP 2006507498A · 2006 [cited by applicant]
JP 2008502921A · 2008 [cited by applicant]
JP 2008541104A · 2008 [cited by applicant]
JP 2011508221A · 2011 [cited by applicant]
JP 2014153243A · 2014 [cited by applicant]
WO 1998021356A1 · 1998 [cited by applicant]
WO 2003019171A1 · 2003 [cited by applicant]
WO 2004053483A2 · 2004 [cited by applicant]
WO 2005052596A1 · 2005 [cited by applicant]
WO 2006122553A1 · 2006 [cited by applicant]
WO 2008028011A2 · 2008 [cited by applicant]
WO 2009053370A1 · 2009 [cited by applicant]
WO 2009082699A1 · 2009 [cited by applicant]
WO 2016096725A1 · 2016 [cited by applicant]
WO WO2016135136 · 2016 [cited by examiner]
WO 2017117565A1 · 2018 [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2019/058009, mailed May 5, 2022, 14 pages. [cited by applicant]
International Search Report and Written Opinion issued in corresponding PCT application No. PCT/US2019/058009, dated Sep. 14, 2020, (20 pages). [cited by applicant]
Invitation to Pay Additional Fees issued in corresponding PCT application No. PCT/US2019/058009, dated Jul. 16, 2020, (16 pages). [cited by applicant]
Yoshimoto et al., crystal structures of creatininase reveal the substrate binding site and provide an insight into the catalytic mechanism, Journal of Molecular Biology, vol. 337, No. 2, Mar. 19, 2004, pp. 399-416. [cited by applicant]
Young et al. Plant Sci. Lett. ( 1984) 34: 203-209 (Year: 1984). [cited by applicant]
Barnet et al. Biological control (2017) 113: 45-57 (Year: 2017). [cited by applicant]
Brooke et al. J. Med. Microbial. (2003) 52: 509-513 (Year: 2003). [cited by applicant]
Machine translation of CN 103609425 B (published May 27, 2015) downloaded from Innovation Plus on Apr. 22, 2022 (Year: 2015). [cited by applicant]
Lin et al. J. Antimicrobial Therapy (1979) 5: 37-44 (Year: 1979). [cited by applicant]
Wei et al. J. Microbial. Immunol. Infection (2017) 50: 821-830 (Year: 2017). [cited by applicant]
MacGowan et al. Clin. Microbial Infect. (1999) 5: 32-36 (Year: 1999). [cited by applicant]
Shimizu et al. (Microbial. Immunol. 1981) 25(8): 773-786 (Year: 1981). [cited by applicant]
Names for Vantocil 1 B from the Registry File on STN downloaded Aug. 14, 2021 (Year: 2021). [cited by applicant]
Final Office Action for U.S. Appl. No. 16/664,264, issued Apr. 27, 2022, (23 pages). [cited by applicant]
Cooper et al., “Creatine supplementation with specific view to exercise/sports performance: an update,” Journal of the International Society of Sports Nutrition, 9(33), (2012), 11 pages. [cited by applicant]
Kwa et al., “Pharmacokinetics of Polymyxin B in a Patient With Renal Insufficiency: A Case Report,” Clin Infect Dis (2011 ), 52(10), 1280-1281 (2011). [cited by applicant]
Final Office Action in U.S. Appl. No. 16/664,264 dated May 30, 2023, 7 pages. [cited by applicant]
Final Office Action in U.S. Appl. No. 17/680,487 dated Apr. 8, 2024, 42 pages. [cited by applicant]
First Office Action in Chinese Application No. 201980042702.7 dated Mar. 30, 2024 [with English translation], 14 pages. [cited by applicant]
Cicerone et al., “Stabilization of Proteins in Solid Form”, Advanced Drug Delivery Reviews, vol. 93, pp. 14-24 (2015), 28 pages. [cited by applicant]
Examiner Requisition in Canadian Application No. 3,104,896 dated Mar. 21, 2024, 6 pages. [cited by applicant]
Conway et al., “Layer-by-layer design and optimization of xerogel-based amperometric first generation biosensors for uric acid,” Journal of Electroanalytical Chemistry, vol. 775, pp. 135-145 (2016), 37 pages. [cited by applicant]
“FDA updates warnings for fluoroquinolone antibiotics,” U.S. Food & Drug Administration, FDA News Release [online] URL:https://www.fda.gov/news-events/press-announcements/fda-updates-warnings-fluoroquinolone-antibiotics… [cited by applicant]
“Hydromed D Series,” AdvanSource Biomaterials, (Apr. 16, 2010) [online] Retrieved from the Internet <URL: http://www.advbiomaterials.com/products/hydrophillic/HydroMed.pdf> [retrieved on Sep. 20, 2019], 3 pages. [cited by applicant]
“HydroThane™,” AdvanSource Biomaterials, (Jun. 21, 2011) [online] Retrieved from the Internet <URL: http://www.advbiomaterials.com/pdf/HydroThane%20Factsheet.pdf> [retrieved on Sep. 19, 2019], 3 pages. [cited by applicant]
Magalhaes et al., “Urea potentiometric biosensor based on urease immobmzed on chitosan membranes,” Talanta, vol. 47, pp. 183-191 (1998), 9 pages. [cited by applicant]
Mohapatra et al., “Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions,” J. Biosci 46:85 (2021), 18 pages. [cited by applicant]
Monošǐk et al., “Application of electrochemical biosensors in clinical diagnosis,” Journal of Clinical Laboratory Analysis, vol. 26(1), pp. 22-34 (2012), 13 pages. [cited by applicant]
Nichols et al., “The effect of nitric oxide surface flux on the foreign body response to subcutaneous implants,” Biomaterials, vol. 33, No. 27, pp. 6305-6312 (2012), 21 pages. [cited by applicant]
Russo et al., “Charge accumulation in electron cryomicroscopy,” Ultramicroscopy, vol. 187, pp. 43-49, DOI: 10.1016/j.ultramic.2018.01.009 (2018), 15 pages. [cited by applicant]
Tjell et al., “Diffusion rate of hydrogen peroxide through water-swelled polyurethane membranes,” Sensing and Bio-Sensing Research, vol. 21, No. 27, pp. 35-39 (2018), 5 pages. [cited by applicant]
Lu et al., “Research and Application of Creatinase”, Bulletin of science and technology, 2009, pp. 437-440. [cited by applicant]
Office Action received for Chinese Patent Application No. 201980103233.5, mailed on Oct. 19, 2024, 15 pages (8 pages of English Translation and 7 pages of Original Document). [cited by applicant]
Office Action received for European Patent Application No. 19804990.0, mailed on Jun. 6, 2025, 6 pages. [cited by applicant]
Killard et al., “Creatinine biosensors: principles and designs”, vol. 18, Issue 10, Oct. 1, 2000, pp. 433-437. [cited by applicant]
Lad et al., “Electrochemical Creatinine Biosensors”, Anal. Chem, vol. 80, Issue 21, Nov. 1, 2008, pp. 7910-7917. [cited by applicant]
Mohabbati-Kalejahi et al., “A review on creatinine measurement techniques”, Talanta, vol. 97, 2012, pp. 1-8. [cited by applicant]
Office Action received for Chinese Patent Application No. 201980103233.5, mailed on Mar. 8, 2025, 11 pages (6 pages of English Translation and 5 pages of Original Document). [cited by applicant]
Pedrozo-Peñafiel et al., “Voltammetric determination of creatinine using a gold electrode modified with Nafion mixed with graphene quantum dots-copper”, Journal of Electroanalytical Chemistry, vol. 878, Dec. 2020, pp. 1… [cited by applicant]